Sanofi (EPA:SAN)
France
· Delayed Price · Currency is EUR | Market Cap | 130.52B |
| Revenue (ttm) | 44.29B |
| Net Income (ttm) | 5.56B |
| Shares Out | 1.25B |
| EPS (ttm) | 4.44 |
| PE Ratio | 23.72 |
| Forward PE | 12.67 |
| Dividend | 3.92 (3.78%) |
| Ex-Dividend Date | May 13, 2024 |
| Volume | 2,172,268 |
| Average Volume | 1,749,008 |
| Open | 102.42 |
| Previous Close | 103.58 |
| Day's Range | 102.42 - 104.12 |
| 52-Week Range | 85.07 - 106.14 |
| Beta | 0.46 |
| RSI | 62.24 |
| Earnings Date | Jan 30, 2025 |
About Sanofi
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; inf... [Read more]
Financial Performance
In 2024, Sanofi's revenue was 44.29 billion, an increase of 7.73% compared to the previous year's 41.11 billion. Earnings were 5.56 billion, an increase of 2.96%.
Financial StatementsNews
Stocks to watch today on 21 Feb: Cipla, Senores, Narayana Hrudayalaya, Sanofi in pharmaceuticals and healthcare sector
The pharmaceuticals and healthcare sector is witnessing significant advancements with new product approvals, strategic acquisitions, and expansions. Key stocks to watch today are: Cipla: Received USFD...
Chronic Spontaneous Urticaria Market to Register Incremental Growth During the Study Period (2020–2034) Owing to the Launch of Emerging Therapies | DelveInsight
New York, USA, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Chronic Spontaneous Urticaria Market to Register Incremental Growth During the Study Period (2020–2034) Owing to the Launch of Emerging Therapies | Del...
Sanofi: OpenAI's Research Agents Could Lead To Explosive Growth
Sanofi to sell 50% stake in consumer health unit to CD&R
Press Release: Sanofi and CD&R sign Opella share purchase agreement
Sanofi and CD&R sign Opella share purchase agreement Paris, February 19, 2025 . Following completion of the required social and corporate procedures, Sanofi and CD&R announce today they have signed th...
Regeneron, Sanofi asthma therapy Dupixent under FDA review for rare skin condition
Sanofi gets FDA approval for NovoLog insulin biosimilar
How Is The Market Feeling About Sanofi?
Sanofi's (NYSE: SNY) short percent of float has fallen 8.33% since its last report. The company recently reported that it has 4.88 million shares sold short , which is 0.22% of all regular shares tha...
Press Release: Filing of the 2024 U.S. Form 20-F and French “Document d'Enregistrement Universel” containing the Annual Financial Report
Filing of the 2024 U.S. Form 20-F and French “Document d'Enregistrement Universel” containing the Annual Financial Report Paris, February 13, 2025. Sanofi announces today the filing of its Form 20-F w...
Sanofi/Johnson & Johnson Partnered Vaccine Against Bacterial Sepsis Flunks Late-Stage Study
Sanofi SA (NASDAQ: SNY) and Johnson & Johnson (NYSE: JNJ) have discontinued the E.mbrace phase 3 study evaluating a vaccine candidate for extraintestinal pathogenic E. coli. The E.mbrace study is a ...
Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study
Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study Independent interim analysis of the E.mbrace phase 3 study finds that the vaccine candidate didn't demonstrate sufficient ef...
Sanofi executes first tranche of €5 billion stock buyback
Sanofi (SNY) launches €5 billion stock buyback program, successfully executing first tranche with €3 billion off-market block trade with L'Oréal.
Healthcare company Sanofi announces share buyback of up to 2 billion euros
French healthcare company Sanofi announced on Friday a share buyback plan worth up to 2 billion euros ($2.1 billion), which would be done between now and the end of December.
Press Release: Execution of a share buyback agreement for up to €2 billion
Execution of a share buyback agreement for up to €2 billion Paris, February 7, 2025. On January 30, 2025, Sanofi announced its intention to execute a share buyback program in 2025 of €5 billion, prefe...
MITEM PHARMA Continues Its Mission to Protect the Interests of Patients Suffering From Rare and Lethal Diseases by Acquiring the FLISINT® Speciality from SANOFI
MASSY, France--(BUSINESS WIRE)--MITEM PHARMA, a French-based pharmaceutical company dedicated to Drugs of Major Therapeutic Interest (DMTI), is pleased to announce that it has acquired the rights to F...
Sanofi Buys Back ~$3 Billion In Shares From L'Oréal: Details
Pharmaceutical and healthcare company Sanofi SA (NASDAQ: SNY) has announced the purchase of 2.3% of its shares from its long-standing investor, L’Oréal SA (OTC: LRLCF), as part of its ongoing share ...
LOreal to Sell $3.1 Billion Stake in Sanofi Back to Pharma Group
L’Oreal sells €3 billion of Sanofi stock back to drugmaker
After the sale, L’Oréal will own 7.2% of Sanofi’s share capital and 13.1% of its voting rights.
L'Oréal to Sell Part of Sanofi Stake for â¬3 Billion
L'Oréal to Sell Part of Sanofi Stake for â¬3 Billion
Press Release: Sanofi announces buy back of shares from L'Oréal
Sanofi announces buy back of shares from L'Oréal Paris, February 3, 2025. Sanofi today announces the acquisition of 2.3% of its shares from long-standing shareholder L'Oréal. This transaction is part ...
Agreement Between L'Oréal and Sanofi for the Repurchase by Sanofi of 2.3% of Its Own Shares Held by L'Oréal
AGREEMENT BETWEEN L'ORÉAL AND SANOFI FOR THE REPURCHASE BY SANOFI OF 2.3% OF ITS OWN SHARES HELD BY L'ORÉAL
Press Release: Sanofi announces buy back of shares from L'Oréal
Sanofi announces buy back of shares from L'Oréal Paris, February 3, 2025. Sanofi today announces the acquisition of 2.3% of its shares from long-standing shareholder L'Oréal.
Press Release: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant
Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant